Antiproliferative effects of pioglitazone involved of nitric oxide on cultured rabbit aortic smooth muscle cells

Abstract

Abstract: AIM: To investigate the antiproliferative effects of pioglitazone (PIO) and its possible mechanisms on the cultured rabbit aortic smooth muscle cells (VSMCs). METHODS: Proliferation of VSMCs was induced by high concentration of glucose and insulin to mimic insulin resistance (IR) status. Cells proliferation and viability were measured by MTT assay. NO content in culture solution and NOS activities of VSMCs were determined by assay kits, respectively. RESULTS: Proliferation of VSMCs were markedly decreased by PIO in all groups (P <0.01). NO content in culture medium and the activities of total NOS and iNOS of VSMCs were significantly increased by PIO in both normal and mimic IR culture condition (P <0.01). The effects of PIO on VSMCs were stronger in mimic IR culture condition than that in normal culture condition, and these effects of PIO were partially blocked by the NOS inhibitor L-NAME. CONCLUSION: The antiproliferative effects of PIO were partially involved in NO pathway on cultured VSMCs both in normal and mimic IR culture condition.

Key words: nitric oxide, nitric oxide synthase, pioglitazone, vascular smooth muscle cell, insulin resistance

CLC Number:

R977.15

CHEN Lu-ying, XU Jiang-ping, PANG Jian-xin, SHI Dao-hua. Antiproliferative effects of pioglitazone involved of nitric oxide on cultured rabbit aortic smooth muscle cells[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2005, 10(6): 642-645.

References

1 Game BA, Maldonado A, He L, Huang Y. Pioglitazone inhibits MMP-1 expression in vascular smooth muscle cells through a mitogen-activated protein kinase-independent mechanism[J]. Atherosclerosis, 2005; 178: 249-56
2 de Dios ST, Bruemmer D, Dilley RJ, Ivey ME, Jennings GL, Law RE, et al.Inhibitory activity of clinical thiazolidinedione peroxisome proliferator activating receptor-gamma ligands toward internal mammary artery, radial artery, and saphenous vein smooth muscle cell proliferation[J]. Circulation, 2003; 107: 2548-50
3 Law RE, Goetze S, Xi XP, Jackson S, Kawano Y, Demer L, et al.Expression and function of PPARgamma in rat and human vascular smooth muscle cells[J]. Circulation, 2000;101: 1311-8
4 张铖, 叶平, 张洁.吡格列酮对左心室肥厚大鼠心肌炎性细胞因子表达的影响[J]. 中国临床药理学与治疗学,2004; 9:658-61
5 Bruemmer D, Berger JP, Liu J, Kintscher U, Wakino S, Fleck E, et al.A non-thiazolidinedione partial peroxisome proliferator-activated receptor gamma ligand inhibits vascular smooth muscle cell growth[J]. Eur J Pharmacol, 2003; 466:225-34
6 Palakurthi SS, Aktas H, Grubissich LM, Mortensen RM, Halperin JA. Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor gamma and mediated by inhibition of translation initiation[J]. Cancer Res, 2001; 61:6213-8
7 Begum N, Ragolia L.High glucose and insulin inhibit VSMC MKP-1 expression by blocking iNOS via p38 MAPK activation [J]. Am J Physiol Cell Physiol, 2000; 278:C81-91
8 郭风劲, 彭惠民, 张政, 晏宁, 周宇箭, 魏倩萍. 2型糖尿病合并高血压患者血清NO、NOS 水平的研究[J]. 中国老年学杂志, 2004;24: 207-8
9 HsuehWA, Jackson S, Law RE.Control of vascular cell proliferation and migration by PPAR-gamma: a new approach to the macrovascular complications of diabetes [J]. Diabetes Care, 2001; 24:392-7
10 Aizawa Y, Kawabe J, Hasebe N, Takehara N, Kikuchi K.Pioglitazone enhances cytokine-induced apoptosis in vascular smooth muscle cells and reduces intimal hyperplasia[J]. Circulation, 2001; 104:455-60
11 Heitzer T, Krohn K, Albers S, Meinertz T. Tetrahydrobiopterin improves endothelium-dependent vasodilation by increasing nitricoxide activity in patients with Type II diabetes mellitus[J]. Diabetologia, 2000;43:1435-8
12 Koshinaka K, Oshida Y, Han YQ, Ohsawa I, Sato Y.The effect of nitric oxide synthase inhibitor on improved insulin action by pioglitazone in high-fructose-fed rats[J]. Metabolism, 2004; 53:22-7
13 Verma S, Arikawa E, Yao L, Laher I, McNeill JH.Insulininduced vasodilation is dependent on tetrahydrobiopterin synthesis[J]. Metabolism, 1998;47: 1037-9
14 Petrie JR, Ueda S, Webb DJ, Elliott HL, Connell JM.Endothelial nitric oxide production and insulin sensitivity. A physiological link with implications for pathogenesis of cardiovascular disease[J]. Circulation, 1996;93:1331-3
15 李瑞峰, 郭成浩, 魏树珍, 陈福琴, 陈融, 李莉, 等.高果糖诱导的胰岛素抵抗大鼠外周血白细胞iNOS mRNA 与ec-NOS mRNA 表达的变化[J]. 中国病理生理杂志, 2002;18:1404-6
16 Bruemmer D, Law RE.Thiazolidinedione regulation of smooth muscle cell proliferation[J]. Am JMed, 2003;115:87S-92S

[1]	QUAN Haiyan, JIANG Xing, HE Lu. Recent progress of mitophagy in hepatic insulin resistance [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(2): 198-204.
[2]	QUAN Haiyan, LIU Yuhuan, YANG Li, YANG Fang, QIN Xuping. Improvement of CGRP on vascular endothelial cells insulin resistance via activation of cAMP/PPARγ/eNOS pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(6): 615-622.
[3]	QIU Fei, GAO Dan, YANG Dongmei, ZHONG Xiaomei, TANG Sha, YIN Huiming, ZHANG Zaiqi. Effects of curcumin on proliferation of VSMCs and expression of PTEN induced by PDGF-BB [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(12): 1358-1363.
[4]	DING Fan, LI Wenxiong, ZHANG Jiali, ZHANG Yan. Research progress on pathology mechanism and treatment target for diabetic sarcopenia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(12): 1428-1433.
[5]	ZHENG Li, MO Juanfen, WU Jiayuan, GUO Li, BAO Yi. Study on the anti-hyperlipidemia mechanisms and signaling pathways of traditional Chinese medicine Polygonum cuspidatum based on network pharmacology [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(10): 1107-1119.
[6]	WANG Rongjun, DING Bo. Mechanism of human urotensin II on myocardial ischemia-reperfusion injury in rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(6): 622-626.
[7]	SONG Meiqing. Effect of metformin on bone mineral density, insulin resistance and cytokines in type 2 diabetes mellitus patients with primary hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(6): 694-698.
[8]	ZHANG Xiaoyi, YU Xiaohua, LIU Yuhuan, YANG Li, WANG Zhen, YANG Fang, QIN Xuping, ZENG Siyu. Role of ERK1/2 and p38MAPK in the expression of Nox1 in A10 vascular smooth muscle cell induced by Ang II and CGRP [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(1): 13-19.
[9]	SHEN Ji-zhong, LIU Hang. Experimental study of a metabolic syndrome mouse model induced by high sucrose-containing drinking water [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(9): 1011-1015.
[10]	ZOU Liu-yi, WANG Mei-rong, NI Lian-song. Effects of ketotifen on insulin resistance in high-carbon hydrate-fat diet rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(7): 761-765.
[11]	QIAN Xiao-dan, LUO Chun-xia, ZHU Dong-ya. nNOS is required for enhancing proliferation of NSCs induced by OGD [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2014, 19(10): 1099-1106.
[12]	ZHANG Yan, YUAN He-ming, HAN Zhen. Pioglitazone improves hepatic oxidative and nitrative stress in metabolic syndrome rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(9): 988-992.
[13]	JIN Wan-bing. Protective effects of puerarin on gentamicin-induced nephrotoxicity in rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(8): 864-867.
[14]	XUE Wan-wan, HONG Hua-shan, LIN Xiao-hong, LIN Jun-hua, FANG Mei-qin. Expression of TRPC in the smooth muscle cells of the small intramyocardial arteries in the left ventricles of spontaneously hypertensive rats [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(8): 879-884.
[15]	LV Hong-le, FU Ping, LI Hua. Role of 20-HETE in diabetic cardiovascular complications [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2013, 18(8): 950-953.